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Abstract
Objective The clinical symptoms of schizophrenia are
associated with serious social, quality of life and func-
tioning alterations. Typically, data on health utilities are
not available in clinical studies in schizophrenia. This
makes the economic evaluation of schizophrenia treat-
ments challenging. The purpose of this article was to
provide a mapping function to predict unobserved utility
values in patients with schizophrenia from the available
clinical and socio-demographic information.
Methods The analysis was performed using data from
EuroSC, a 2-year, multi-centre, cohort study conducted in
France (N = 288), Germany (N = 618), and the UK
(N = 302), totalling 1208 patients. Utility was calculated
based on the EQ-5D questionnaire. The relationships
between the utility values and the patients’ socio-demo-
graphic and clinical characteristics (Positive and Negative
Syndrome Scale—PANSS, Calgary Depression Scale for
Schizophrenia—CDSS, Global Assessment of Function-
ing—GAF, extra-pyramidal symptoms measured by Barnes
Akathisia Scale—BAS, age, sex, country, antipsychotic
type) were modelled using a random and a fixed individual
effects panel linear model.
Results The analysis demonstrated the prediction ability
of the used parameters for estimating utility measures in
patients with schizophrenia. Although there are small
variations between countries, the same variables appear to
be the key predictors. From a clinical perspective, age,
gender, psychopathology, and depression were the most
important predictors associated with the EQ-5D.
Conclusion This paper proposed a reliable, robust and
easy-to-apply mapping method to estimate EQ-5D utilities
based on demographic and clinical measures in
schizophrenia.
Keywords Schizophrenia  Quality of life  Positive and
Negative Syndrome Scale  Mapping
Introduction
Economic evaluation allows comparing several alternative
therapies in terms of benefit brought by a new treatment
and associated costs. The comparison is often conducted by
the calculation of incremental cost-effectiveness ratio
(ICER). Cost-utility analysis is a common type of eco-
nomic evaluation in which product effectiveness is
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expressed in quality-adjusted life years (QALYs). QALYs
are determined by multiplying life years gained using the
therapy by utilities, corresponding to patient’s quality of
life (QoL) during this period. Utility of a certain health
state accounts for different aspects of QoL and corresponds
with the desire or preference that individuals exhibit for
this state. Unlike psychometric measures that consider only
the degree of abnormality of an impairment of health,
utility preference-based measures allow estimating the
significance of the impairments and so can be used in
economic evaluation to assess the value of interventions
from the perspective of the patient. A number of instru-
ments have been developed to measure preference-based
utilities directly, or through generic or disease-specific
preference-based questionnaires. However, in the context
of developing cost-utility models, utility measurements are
rarely available and are sometimes predicted using map-
ping extrapolation from a clinical questionnaire and other
parameters [10].
Schizophrenia is chronic mental disorder which signifi-
cantly impacts patient’s QoL [11, 12, 34]. It affects
approximately 1 % of the general population, and onset
usually occurs before the age of 25 years [28].
Schizophrenia symptoms are generally devised in positive
symptoms (psychotic behaviours not seen in healthy people,
i.e. hallucination, delusions, etc.), negative symptoms (de-
crease or loss of normal functions, i.e. apathy, lack of
emotions), and cognitive symptoms. The key component of
schizophrenia treatment is antipsychotic medications which
are mainly used to manage positive symptoms. There exist
two generations of antipsychotic drugs called typical (first
generation) and atypical (second generation) antipsychotics.
There is a large range of symptoms and treatment-re-
lated adverse events, and these are associated with serious
functioning, social, and QoL alterations in patients with
schizophrenia. This makes the utility assessment chal-
lenging. In 2010, Mavranezouli reported that seven utility
or cost-utility analyses were performed for schizophrenia
treatment [29]. Out of these analyses, none of the studies
used utility values for schizophrenia which had been gen-
erated by using EQ-5D, otherwise widely used in cost-
utility analyses and a preferred instrument of the National
Institute for Health and Clinical Excellence NICE [32].
Therefore, developing a predictive equation to estimate
utility measures based on clinical, functioning, and QoL
variables would support and simplify health economics
assessment of therapies designated to treat patients suf-
fering from schizophrenia.
Several studies have investigated the independent pre-
dictors of QoL in people with schizophrenia. These studies
report that clinical factors, such as positive and negative
symptoms, depression, and extra-pyramidal symptoms, are
associated with low QoL [2, 14, 22, 27, 33, 36, 38, 39, 43].
The objective of this article is to generate a predictive
equation for EQ-5D utility in schizophrenia which would
allow its extrapolation from other instruments and clinical
parameters, using data from the European Schizophrenia
Cohort (EuroSC). Two predictive models were developed
by using two sets of variables in order to take into account
differences in the availability of clinical data to practi-
tioners. Additionally, a predictive model for SF-6D utilities
was developed to study mapping mechanisms and to
determine whether mapping the same set of predictors to
the utilities collected, using the two different instruments,
conforms to a different algorithm.
Data and methods
Design and sample
The EuroSC is a European cohort conducted in France,
Germany, and the UK with a prospective follow-up from
1998 to 2001. A total of 1208 participants were interviewed
at 6-month intervals for a total of 2 years in France
(N = 288), Germany (N = 618), and the UK (N = 302).
This study was sponsored by H. Lundbeck A/S.
The first objective of the study was to identify and
describe the types of treatments and methods of care for
patients with schizophrenia and to correlate these treat-
ments with clinical outcomes, states of health, and QoL. In
each country, catchment areas were chosen based on socio-
demographic factors and on the styles of service delivery.
Nine European centres were considered: two in Britain,
four in Germany, and three in France. The participants
were selected to provide a representative sample of the
patients treated in secondary psychiatric services in each
catchment area.
Random sampling from these patients was used to
generate a representative sample. This project was con-
ducted in accordance with the Declaration of Helsinki and
French Good Clinical Practices [5, 42]. A description of the
rationales and methods of the study is presented in Beb-
bington et al. [7].
Data collection and instruments
Collected data included utility measures, socio-demo-
graphic characteristics, and clinical and treatment infor-
mation. Patients’ health states were assessed using Positive
and Negative Syndrome Scale (PANSS) [9, 24], Calgary
Depression Scale for Schizophrenia (CDSS) [1], and global
assessment of functioning (GAF) [17], and extra-pyramidal
symptoms were measured by Barnes Akathisia Scale
(BAS) [6].
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The utility measures were computed from the multi-
attribute EuroQol EQ-5D questionnaire [13, 23, 40], using
the British scoring formula. EQ-5D measures five dimen-
sions: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. Each dimension has three cate-
gories of severity: indicating no problem, some problem,
and extreme problems. Patients are asked to choose the
severity level for each dimension that corresponds most to
his health state according to his perception. In such a
manner each health state is coded by a five-digit number,
which can be derived into utility [15]. EQ-5D covers a total
of 243 health states.
Together with EQ-5D, health-related QoL was asses-
sed using SF-6D questionnaire [41]. The SF-6D is a
revision of the SF-36 questionnaire, the most widely used
generic instrument to measure general health in clinical
studies, as the latter cannot be used for economic eval-
uation in its original form. The SF-6D allows for the
economic evaluation and covers six domains including
physical functioning, role limitation, social functioning,
pain, mental health, and vitality. Any patient who com-
pletes the SF-36 can be classified according to the SF-6D
derived value.
Available socio-demographic and treatment informa-
tion included the country of origin (country), age of the
patient at the date of the visit (age), gender (sex being 1
for males and 0 for females), and antipsychotic type
(ATYP)—typical, atypical, or mixed (containing at least
one typical antipsychotic and one atypical
antipsychotic).
Symptoms severity was measured using PANSS, a
comprehensive tool that includes 30 items and requires an
individual interview with each patient (30–40 min). The
items are assessed based on the patient’s perceptions of
their experiences in the previous week. The interview
covers the following domains: positive sub-score
(PANSS_POS), negative sub-score (PANSS_NEG), and
general psychopathology sub-score (PANSS_PSY). The
PANSS_POS and PANSS_NEG contain seven and the
PANSS_PSY contains 16 items all ranging from 1
(minimal problem) to 7 (extreme problem).
Depressive symptoms were assessed using CDSS,
containing nine items with four possible severity levels
(range from 1 to 27). Moreover, patient states were
examined employing GAF scale, commonly used to
assess psychological, social, and occupational functioning
in mental health illness (range 1–100). Extra-pyramidal
symptoms were assessed using BAS—a specific scale
developed to determine the severity of drug-induced
Akathisia. BAS includes objective and subjective items as
well as global clinical assessment of the Akathisia score
(range 1–100).
Predictive models
Two predictive models were developed using two sets of
independent variables. Both models are summarized in
Eq. 1 and Eq. 2. Negative EQ-5D values were allowed to
account for very severe health states; consequently, EQ-5D
variable was ranged from minus infinite to one. The EQ-5D
variable was then considered by approximation as a con-
tinuous variable. Since variables are observed by individ-
uals and by time, panel models were considered as
appropriate. In addition, fixed and random effects by
patient were introduced in the statistical models to account
for patients’ heterogeneity.
EQ  5Qit ¼ aþ b1  PANSS POSit
þ b2  PANSS NEGit þ b3  PANSS PSYit
þ b4;1  Ageit þ b4;2  Age2it þ b5  Sexi
þ b6  FRi þ b7  GEi þ ui þ eit;
ð1Þ
EQ  5Qit ¼ aþ b1  PANSS POSit þ b2  PANSS NEGit
þ b3  PANSS PSYit þ b4;1  Ageit
þ b4;2  Age2it þ b5  Sexi þ b6  FRi
þ b7  GEi þ b8  AP1it þ b9  AP2it
þ b10  CDSSit þ b11  GAFit
þ b12  BASit þ ui þ eit;
ð2Þ
ui i:i:d:N 0; r2i
 
for the random individual effect model,
eit  i:i:d:N 0; r2e
 
; where FRi and GEi are dummy vari-
ables for France and Germany, respectively, AP1 = 1 if
AP is ‘‘Mixed’’, 0 otherwise; AP2 = 1 if AP is ‘‘Only
Atypical’’, 0 otherwise; the complement is when AP is
‘‘Only Typical’’. i = 1,…,N is the individual dimension,
and t = 1,…,5 is the time dimension. The indices i corre-
spond to the patients, and t represents the visit number
(1–5). eit is an error term specific to individual i at visit t,
and ui is an error term specific to individual i. Here, it is
assumed that corr (ui, X) = 0, which will be tested with the
Hausman’s test.
To verify the strength of the estimates, the models were
also estimated with the error terms eit following an
autoregressive process of order one, denoted AR [10].
The same models were also applied to the SF-6D utility
measures using a similar methodology.
Finally, Ara et al. [4] recently showed that least-squares
statistical models may perform well on the aggregate level,
but that predicting preference-based utility values using
partial proportional odds models (PPOM) and recon-
structing the ED-5D global score from these sub-scores
may perform better than using a conventional linear
Qual Life Res (2016) 25:925–934 927
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statistical model. In the case of schizophrenia data, the
various probabilities are not affected by the same variables.
Consequently, a more general and appropriate model, the
universal multi-nomial logit model (UMLM) [31], may be
used. The results of the UMLM may be useful to recon-
struct the EQ-5D global score from the sub-scores and also
to account for different tariffs depending on the countries.
The model and the results are presented in online
resources.
Statistical analysis
Descriptive analyses were conducted for all variables, and
correlation structures were examined.
In case of high correlation between explanatory vari-
ables, the relevant variables cannot be selected with respect
to their statistical significance as it may result in the
selection of collinear variables and estimation biases.
Therefore, an alternative method was used for the variable
selection: An approach similar to that of the principal
components analysis (PCA) was conducted by selecting
variables with the highest contribution to the variance.
Contribution to the variance was assessed iteratively with
removing the variable that had shown the highest contri-
bution to the variance at the previous step.
To assess the selection bias, two sub-samples were
considered: a sub-sample with no missing data and a sub-
sample with missing values in at least one of the following
variables: EQ-5D, PANSS_POS, PANSS_NEG,
PANSS_PSY, age, sex, ATYP, CDSS, GAF, or BAS. No
missing data for the country variable were found. Mean
values for all the variables were compared between sub-
samples, using Student tests or Chi-square tests, as
appropriate.
To assess the predictive power of the developed models,
two measures of error were calculated: the mean absolute
error—the average of the absolute differences between the
observed and the predicted values (MAE), and the root-
mean-squared error—the square root of the average of the
squared differences between the observed and predicted
values (RMSE) [19].
In order to conduct a cross-validation, the sample was
split randomly (each observation had a probability p to be
selected in the training set, where p was chosen arbitrarily).
Here, p = 0.5, p = 0.25 and p = 0.1 were chosen. How-
ever, the prediction error may vary depending on the
sample partition. Consequently, to reduce the variability,
multiple rounds of cross-validation were performed using
different partitions, and the results were averaged among
the rounds. A total of 1000 rounds were performed, and
random selection was made for each round.
STATA software was used for all analyses.
Results
Descriptive results are presented in Table 1. The mean
patient age was 41.8 years. Males were more prevalent in
the cohort (63 vs. 37 %). The mean PANSS was about 55,
corresponding to ‘‘mildly ill’’ state.
The correlation structure of the explanatory variables is
summarized in Table SS1 (see Online resource). A strong
correlation was observed between the PANSS_POS and
PANSS_PSY scores (0.71), the PANSS_NEG and
PANSS_PSY scores (0.69), and the PANSS_NEG and GAF
scores (-0.5). The Hausman’s test showed that the correla-
tion between the variables led to the co-linearity and would
cause estimation biases, justifying the choice of the proce-
dure for variable selection.
No significant difference was observed in the variables
means between the sample without missing values and the
sample with at least one missing value for all patients (see
Table SS2 in Online resource). Both sub-samples were
very close, thus confirming the absence of selection bias.
Predictive model 1: using only the PANSS scores
The results for variable selection are presented in
Table SS3 (see Online resource). The first relevant variable
was PANSS_PSY with a contribution to R2 of 8.75 %.
When PANSS_PSY effect had been removed, none of the
variables demonstrated a large contribution to R2 (less or
equal to 1 %). In the final model, sex and age variables
were retained as well, because they were available in all the
studies. PANSS_NEG had a negligible contribution to R2
(0.68 %) and was highly correlated with PANSS_PSY
(69 %); it was therefore not used in the analyses.
The model estimates based on PANSS score only are
presented in Table 2. PANSS_PSY and AGE variables had
negative effects on the EQ-5D, whereas the male gender
had a positive effect.
The model for the EQ-5D was also estimated with error
terms following an AR [10] process. Small autocorrelation
was observed (the estimated autocorrelation coefficient is
0.1786), but the estimated coefficients of the model with
AR [10] error terms did not change with respect to the
original model without AR [10] error terms. The Haus-
man’s test was applied and did not reveal any correlation
between ui and X (the p value is 0.1866). Consequently, the
GLS estimator of the panel model was consistent. The
normality hypothesis was rejected (the p values for skew-
ness = 0, for kurtosis = 3, and for the Jarque–Bera test are
0.0000). However, the skewness and the kurtosis were not
large (respectively -1.1125 and 5.8921), and the proba-
bility density function was roughly unimodal, as can be
seen from the kernel density estimate of the residuals in
928 Qual Life Res (2016) 25:925–934
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Fig. 1a (Kernel density estimation is a nonparametric
method for estimating the probability density function of a
random variable.) Finally, the test of Ramsey reset for
linearity of the model was applied, and the null hypothesis
of linearity was rejected (the p value is 0.0130).
Predictive model 2: using additional covariates
The results for variable selection are presented in Table SS3
(see Online resource). Three variables were considered rel-
evant: CDSS (contribution to R2 = 16.27 %), PANSS_PSY
Table 1 Descriptive statistics
Variable Proxy for Mean SD Min Max
AGE (in years) Age 41.80 10.88 18.70 66.62
Multi-attribute EuroQol EQ-5D score Utility 0.76 0.26 -0.43 1.00
SF-6D score Health-related QoL 0.71 0.13 0.30 1.00
Positive sub-score (PANSS_POS) Symptoms severity 11.71 5.13 7 35
Negative sub-score (PANSS_NEG) Symptoms severity 15.39 7.16 7 43
General psychopathology sub-score (PANSS_PSY) Symptoms severity 27.87 9.65 16 71
Calgary Depression Scale for Schizophrenia (CDSS, range from 1 to 27) Depressive symptoms 2.49 3.41 0 21
Global Assessment of Functioning (GAF, range 1–100) Functioning 52.04 15.66 0 99
Barnes Akathisia Scale (BAS, range 1–100) Extra-pyramidal symptoms 1.02 2.12 0 36
Variable Proxy for N %
Proportion of males Gender 2593 63
Proportion of French patients Country 906 22
Proportion of German patients 2099 51






Proportion of only atypical 1194 29
Proportion of only typical 2181 53
Table 2 EQ-5D predictive
model estimates
EQ-5D Coef. Std. Err z p[ |z| [95 % Conf. interval]
Model 1 (PANSS score only)
Constant term 1.026055 0.0277925 36.92 0.000 0.971583 1.080527
PANSS_PSY -0.0076876 0.0004386 -17.53 0.000 -0.0085473 -0.006828
Sex 0.0457537 0.0120427 3.80 0.000 0.0221504 0.0693569
Age -0.0020646 0.0005313 -3.89 0.000 -0.0031059 -0.0010233
Model 2 (PANSS score and additional covariates)
Constant term 1.011187 0.025353 39.88 0.000 0.9614961 1.060878
CDSS -0.0192384 0.0011701 -16.44 0.000 -0.0215317 -0.016945
PANSS_PSY -0.0047262 0.0004566 -10.35 0.000 -0.005621 -0.0038314
Age -0.0023449 0.0004802 -4.88 0.000 -0.003286 -0.0014038
Sex 0.0322763 0.0108972 2.96 0.003 0.0109182 0.0536345
Model 1 (PANSS score only): number of observations = 4471, number of groups = 1181. R2:
within = 0.0394, between = 0.1500, overall = 0.1035. Wald test for significance (*v2(3)) = 334.57
(p value = 0.0000). ru = 0.1697, re = 0.1842, q = 0.4589 (fraction of variance due to ui). Breusch and
Pagan Lagrangian multiplier test for random effects (*v2(1)) = 1324.56 (p value = 0.0000)
Model 2 (PANSS score and additional covariates): number of observations = 4470, number of
groups = 1181. R2: within = 0.0615, between = 0.2958, overall = 0.1922. Wald test for significance
(*v2(3)) = 649.19 (p value = 0.0000). ru = 0.1458, re = 0.1821, q = 0.3906 (fraction of variance due
to ui). Breusch and Pagan Lagrangian multiplier test for random effects (*v
2(1)) = 979.44
(p value = 0.0000)
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(contribution to R2 = 3.10 %), and AGE (contribution to
R2 = 1.30 %). In the final model, SEX (contribution to
R2 = 0.45 %) variable was included as well.
The model estimates based on PANSS score and
additional covariates are presented in Table 2. The
Hausman’s test p value is 0.0000. Consequently, there
existed a correlation between ui and X, and the GLS
estimator of the panel model was inconsistent. Fixed
individual effect model estimates were then calculated
and compared to the random individual effect model
estimates (see Table SS4 in Online resource). The
problem arose from CDSS variable, which might be
correlated with the random individual effect ui (the fixed
effect estimate minus the random effect esti-
mate = 0.00679, with standard error of 0.0007483). The
fixed effect model was consistent under this hypothesis
and led to a CDSS coefficient estimate of -0.0124, with
a confidence interval of [-0.0151; -0.0097].
The model was also estimated with error terms fol-
lowing an AR [10] process. Small autocorrelation was
observed (the estimated autocorrelation coefficient is
0.1706), but the estimated coefficients of the model did
not change. The normality hypothesis was still rejected
(the p values for testing skewness = 0, for testing kur-
tosis = 3, and for the Jarque–Bera test are 0.0000).
However, the skewness and kurtosis were not substantial
(-1.1350 and 5.8888, respectively), and the probability
density function was roughly unimodal (see the kernel
density estimate of the residuals in Fig. 1c). Finally, the
Ramsey reset test for linearity was applied, and the null
hypothesis of linearity was retained (the p value is
0.1645).
Fig. 1 Probability density function estimates of the regressions,
residuals. The figures present the residual probability density function
estimates of the various regression models. The probability density
functions are estimated using a nonparametric method based on a
kernel density estimator
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Predictive models for the SF-6D
The same methodology used for the EQ-5D is used for the
SF-6D.
Detailed results on the variable selection are available in
Table SS2 (see Online resource).
The estimates for SF-6D model based on PANSS score
only and on PANSS score and additional covariates are
presented in Table 3. The results are similar to those for the
EQ-5D. The PANSS_PSY negatively affects the utility
measure, whereas male gender affects it positively.
In case of SF-6D model based on PANSS score and
additional covariates, a better estimate for CDSS was
provided by the fixed effect model: -0.0067173 with a
confidence interval of [-0.0080064, -0.0054282]. Again,
the results are similar to those of EQ-5D, suggesting that
both the algorithms are robust.
The same specification tests as for the EQ-5D were
applied to the both SF-6D models. Minor autocorrelation
was observed; however, the estimated coefficients of the
model did not change. The normality hypothesis was again
rejected (the p value for testing skewness = 0 is 0.004, the
p value for testing kurtosis = 3 is 0.0000, and the p value
for the Jarque–Bera test is 0.0000). However, the skewness
and the kurtosis were close to 0 and 3, respectively. In
addition, the probability density function was unimodal and
close to the Gaussian probability density function (see the
kernel density estimate of the residuals in Fig. 1b, d). The
null hypothesis of linearity was rejected (Ramsey reset
p value = 0.0000).
Measuring predictive ability and cross-validation
The predictive errors for the various models are presented
in Table 4. The results for the cross-validation are reported
in the same table for facilitating the comparison. Various
proportions p of the observations used to construct the
training set were chosen to verify the strength of the
models; p = 0.5, 0.25, and 0.1 were tested.
RMSE and the MAE values were similar for all analy-
ses, showing no increase depending on the training set size.
It can be concluded that the models are robust and can be
used to predict the utility measure for other datasets.
Discussion
This study aimed to build a model to map the demographic
and clinical measures of patients with schizophrenia to EQ-
5D index. Although the EQ-5D is currently recommended
by NICE [32] for use in economic evaluation, it remains
largely under-utilized in clinical trials for schizophrenia.
As suggested by the NICE [32], mapping can be used when
EQ-5D is not included in clinical trials. The proposed
mapping functions can constitute the first step in promoting
the assessment of utility values in schizophrenia as
required in cost-utility analyses. Our findings suggest that
the mapping relationship between the socio-demographic,
clinical characteristics, and EQ-5D is reliable and robust.
From a clinical perspective, age, gender, PANSS psy-
chopathology score, and CDSS score are the most
Table 3 SF-6D predictive
model estimates
SF-6D Coef. Std. Err z p[ |z| [95 % Conf. interval]
Model 1 (PANSS score only)
Constant term 0.7958439 0.0073481 108.31 0.000 0.781442 0.8102459
PANSS_PSY -0.0037952 0.0002124 -17.86 0.000 -0.0042115 -0.0033788
Sex 0.0243601 0.0058699 4.15 0.000 0. 0128554 0.0358648
Model 2 (PANSS score and additional covariates)
Constant term 0.8198619 0.0124882 65.65 0.000 0.7953856 0.8443382
CDSS -0.009496 0.0005595 -16.97 0.000 -0.0105926 -0.0083993
PANSS_PSY -0.0021323 0.0002253 -9.46 0.000 -0.002574 -0.0016907
BAS -0.0040303 0.000773 -5.21 0.000 -0.0055454 -0.0025152
Age -0.0008743 0.0002373 -3.68 0.000 -0.0013394 -0.0004092
Sex 0.0139095 0.0053836 2.58 0.003 0.0033579 0.0244612
Model 1 (PANSS score only): number of observations = 4338, number of groups = 1169. R2:
within = 0.0460, between = 0.1306, overall = 0.1036. Wald test for significance (*v2(3)) = 327.86
(p value = 0.0000). ru = 0.0840, re = 0.0856, q = 0.4904 (fraction of variance due to ui). Breusch and
Pagan Lagrangian multiplier test for random effects (*v2(1)) = 1653.046 (p value = 0.0000)
Model 2 (PANSS score and additional covariates): number of observations = 4258, number of
groups = 1166. R2: within = 0.0812, between = 0.2908, overall = 0.2166. Wald test for significance
(*v2(3)) = 704.73(p value = 0.0000). ru = 0.0687, re = 0.0874, q = 0.3819 (fraction of variance due to
ui). Breusch and Pagan Lagrangian multiplier test for random effects
(*v2(1)) = 1212.22(p value = 0.0000)
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important predictors associated with EQ-5D. These find-
ings are consistent with those of the studies focusing on
non-preference-based health status measures. Age nega-
tively affects the utility measure. This is in line with
Kemmler et al. [25] results, showing that social problems,
isolation, and stigmatization of patients with schizophrenia
tend to increase with age. Male gender positively affects
utility measures. This finding appears to be consistent with
the general literature, in which the quality of life of female
patients is often reported to be lower than that of men,
especially with regard to psychological and mental health
domains [21, 35]. Regarding the influence of the PANSS
scores, PANSS psychopathology factor was found to neg-
atively affect the utility (p\ 0.001), whereas the PANSS
positive and negative factors do not affect utility measures.
Similarly to the PANSS psychopathology factor, CDSS
score negatively affects the utility (p\ 0.001). These
findings concur with those of several studies and meta-
analyses that reveal that symptoms have only a modest
relationship with quality of life and that general psy-
chopathology symptoms (e.g. anxiety and depression) were
the most important predictors [8, 16, 20]. Finally, extra-
pyramidal symptoms (BAS) are associated with lower
utility measures. In point of fact, the burden of the side
effects has been extensively explored as a predictor of poor
medication adherence, relapse, and poor QoL [3, 18, 21].
From a methodological aspect, the high co-linearity
among the explanatory variables led to the inappropriate-
ness of variable selection based on the statistical signifi-
cance. A specific procedure employing the principle of
PCA was then developed and applied. Inconsistent
parameter estimates were obtained for the EQ-5D random
effect model based on PANSS score and additional
covariates because of the correlation between some
explanatory variables and the errors terms. The estimates
were then recalculated using the fixed effects panel model,
which provided consistent results. Additionally, a number
of other specification tests were performed in order to
provide the evidence that the proposed mappings model is
well specified and reliable. Finally, the proposed approach
was also tested with SF-6D. The results were coherent with
those obtained for EQ-5D confirming the robustness of the
method. In their paper, McCrone et al. [30] showed that
from an analytical perspective, the SF-6D has advantages
over the EQ-5D due to its normal distribution and the lack
of ceiling effect. However, both measures produced similar
mean utility scores, and further comparisons of the EQ-5D
and SF-6D were required. Additionally, the prediction
errors were calculated using RMSE and MAE. Their values
remained moderate. For the EQ-5D model, RMSE was
around 0.25 and MAE was approximately 0.18. SF-6D
model prediction errors were quite lower (RMSE and MAE
Table 4 Predictive error
results: Predicted versus
observed
Dependent variable Independent variables Mean Min Max Corr RMSE MAE
EQ-5D Observed 0.758 -0.429 1 1 0 0
EQ-5D Only PANSS 0.752 0.369 0.907 0.321 0.246 0.182
EQ-5D Only PANSSa 0.753 0.362 0.905 0.328 0.250 0.184
EQ-5D Only PANSSb 0.755 0.367 0.924 0.316 0.248 0.182
EQ-5D Only PANSSc 0.735 0.219 0.930 0.317 0.246 0.186
EQ-5D Additional 0.753 0.251 0.920 0.438 0.234 0.173
EQ-5D Additionala 0.754 0.314 0.917 0.442 0.234 0.173
EQ-5D Additionalb 0.753 0.230 0.919 0.439 0.235 0.174
EQ-5D Additionalc 0.750 0.114 0.910 0.433 0.234 0.173
SF-6D Observed 0.707 0.301 1 1 0 0
SF-6D Only PANSS 0.704 0.514 0.775 0.328 0.119 0.098
SF-6D Only PANSSa 0.706 0.552 0.774 0.342 0.119 0.098
SF-6D Only PANSSb 0.702 0.552 0.773 0.342 0.119 0.097
SF-6D Only PANSSc 0.703 0.512 0.765 0.325 0.120 0.098
SF-6D Additional 0.704 0.466 0.782 0.465 0.112 0.091
SF-6D Additionala 0.708 0.441 0.788 0.454 0.112 0.092
SF-6D Additionalb 0.703 0.422 0.785 0.457 0.112 0.091
SF-6D Additionalc 0.706 0.399 0.786 0.466 0.112 0.092
Cross-validation
a Training set: 50 % of the original sample (drawn randomly), validation set: 50 %
b Training set: 25 % of the original sample (drawn randomly), validation set: 75 %
c Training set: 10 % of the original sample (drawn randomly), validation set: 90 %
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were about 0.12 and 0.10, respectively). The cross-vali-
dation results confirmed the stability of the models. It may
be concluded that the models are applicable to predict
utility measures.
It should be noted that the EQ-5D value theoretically range
from minus infinite to one. In the original data, the range is
[-0.429; 1.000]; however, the range of predicted values is
[0.114; 0.930]. A similar pattern is observed for SF-6D. Pre-
dictive models generate predictions of the conditional mean,
but not of the conditional variance and thus may compress the
range of individual predicted values. The variance can be
accounted for by using the predicting interval instead of the
predicting value. Siani et al. [37] show how to account for
uncertainty in the context of mapping prediction.
Regarding the analysis limitations, the representative-
ness of the sample should first be discussed. Although the
sampling procedure for the EuroSC aimed to provide a
representative patients sample, this cohort included mostly
paranoid schizophrenia and is characterized by long-term
illness. Moreover, the difference in severity between
excluded and included patients was observed (with higher
clinical severity in excluded patients). Further analysis is
therefore required, using larger and more diverse groups of
patients. However, the large sample size of the presented
study and the longer follow-up allowed overcoming the
limitations of past studies [26].
Conclusion
Because treatments for schizophrenia have significant
effects on the quality of life of patients, reliable methods
for economic evaluations are needed to account for effects
of treatment, to assess utility values, and to calculate
QALYs for further cost-utility analyses. This paper pro-
poses reliable, accurate, and easy-to-apply mapping models
for EQ-5D index based on demographic and clinical
measures in schizophrenia. An advantage of these mapping
functions is the use of generally available in clinical trials
data, such as PANSS score, which expands its
applicability.
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